Showing results (931-940 of 1,147) with videos related to
Sort By:
Pageof 115
Journal of Hepatocellular Carcinoma|April 21, 2025
Optimizing Treatment Selection for Early Hepatocellular Carcinoma Based on Tumor Biology, Liver Function, and Patient StatusXing Li, Yong Xu, Yanmei Ou, et al.Journal of Hepatocellular Carcinoma|April 21, 2025
Serum Osteopontin Enhances Hepatocellular Carcinoma Diagnosis and Predicts Anti-PD-L1 Immunotherapy BenefitMiantao Wu, Fei Zou, Suyin He, et al.Journal of Hepatocellular Carcinoma|April 23, 2025
A Novel Prognostic Signature Integrating Immune and Glycolytic Pathways for Enhanced Prognosis and Immunotherapy Prediction in Hepatocellular CarcinomaZeyu Zhang, Hongxi Zhao, Pengyu Wang, et al.Journal of Hepatocellular Carcinoma|November 17, 2025
Pathogenesis of NAFLD-Related Hepatocellular Carcinoma: An Up-to-Date ReviewYinghui Gao, Ruirui Zhu, Jianxia Dong, et al.Journal of Hepatocellular Carcinoma|September 16, 2025
Radiation-Induced Liver Injury: An OverviewJing Sun, Hao-Ran Lu, Jian-Hui Wu, et al.Journal of Hepatocellular Carcinoma|August 18, 2025
Transarterial Chemoembolization Following Curative Resection May Not Improve Survival for Hepatitis B Virus Associated Intrahepatic Cholangiocarcinoma: Propensity Score Weighting AnalysisGuofang Liu, Wendi Liu, Fuping Zhou, et al.Journal of Hepatocellular Carcinoma|August 11, 2025
GALNT14 Genetic Variants Harbor Differential Prognostic Values Linking to Distinct Macrophage Cell Types in Hepatocellular CarcinomaYu-De Chu, Pei-Huan Ho, Wei-Ting Chen, et al.Journal of Hepatocellular Carcinoma|September 8, 2025
Efficacy and Safety of Different Doses of Bevacizumab Combined with Atezolizumab in Unresectable Hepatocellular CarcinomaShaobo Zhang, Jiabei Wang, Zebin Zhu, et al.Journal of Hepatocellular Carcinoma|September 22, 2025
Methodological Quality of Systematic Reviews on Treatments for Liver Cancer: A Cross-sectional StudyBilly Z Z Cheng, Betty H Wang, Claire Chenwen Zhong, et al.Journal of Hepatocellular Carcinoma|September 22, 2025
A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular CarcinomaWeihong Ma, Yinyin Li, Yinying Lu, et al.Pageof 115